{
    "clinical_study": {
        "@rank": "161367", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "ABT-414 in combination with radiation and temozolomide"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "ABT-414 in combination with temozolomide"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "ABT-414 monotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with\n      glioblastoma multiforme."
        }, 
        "brief_title": "Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioblastoma Multiforme", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Glioblastoma Multiforme (GBM)\n\n          2. 70 or above on Karnofsky Performance Status\n\n          3. Adequate bone marrow function\n\n          4. For Arm A, subject has newly diagnosed GBM and prior surgical resection\n\n          5. For Arm B, subject has newly diagnosed GBM and has completed adjuvant radiation\n             and/or temozolomide therapy or has recurrent GBM per RANO Criteria\n\n          6. For Arm C, subject has recurrent GBM per RANO Criteria\n\n        Exclusion Criteria:\n\n          1. For subjects with newly diagnosed GBM, subject has received prior chemotherapy or\n             radiotherapy for cancer of head and neck region\n\n          2. For Subjects with recurrent GBM in Arm B, subject has received prior treatment with\n             bevacizumab, nitrosourea, or has secondary GBM\n\n          3. For Subjects with recurrent GBM in Arm C, subject has received prior treatment with\n             bevacizumab, or has secondary GBM\n\n          4. Allergies to temozolomide, dacarbazine, IgG containing agents\n\n          5. Anti-cancer treatment 28 days prior to study Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800695", 
            "org_study_id": "M12-356", 
            "secondary_id": "2012-003884-23"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C"
                ], 
                "description": "ABT-414 will be administered by intravenous infusion", 
                "intervention_name": "ABT-414", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Temozolomide will be administered per label and local prescribing regulations.", 
                "intervention_name": "Temozolomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "Whole Brain radiation will be administered in 30 fractions.", 
                "intervention_name": "Whole Brain Radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Temozolomide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "GBM", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Site Reference ID/Investigator# 106817"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 106817", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "Site Reference ID/Investigator# 106816"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 106816", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Site Reference ID/Investigator# 95737"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 95737", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Site Reference ID/Investigator# 127615"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 127615", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Site Reference ID/Investigator# 92313"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 92313", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78258"
                    }, 
                    "name": "Site Reference ID/Investigator# 90773"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 90773", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "zip": "3084"
                    }, 
                    "name": "Site Reference ID/Investigator# 90833"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 90833", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3075 EA"
                    }, 
                    "name": "Site Reference ID/Investigator# 92294"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 92294", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme", 
        "overall_contact": {
            "email": "erica.gomez@abbvie.com", 
            "last_name": "Erica  Gomez, BA", 
            "phone": "847-936-1343"
        }, 
        "overall_contact_backup": {
            "email": "judee.fischer@abbvie.com", 
            "last_name": "JuDee  Fischer, BA", 
            "phone": "8479382512"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Kyle  Holen, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluation of clinical lab testing, adverse event monitoring, and evaluation of vital signs, physical exam, and electrocardiogram (ECG) (periodic)", 
                "measure": "Safety (Number of subjects with adverse events and/or dose limiting toxicities)", 
                "safety_issue": "Yes", 
                "time_frame": "Every week for an expected average of 34 weeks"
            }, 
            {
                "description": "Cmax, Cmin, and half-life", 
                "measure": "Pharmacokinetic profile (Arm A and Expanded Cohort A)", 
                "safety_issue": "Yes", 
                "time_frame": "Multiple timepoints in Week 1 through Week 9 and then throughout maintenance cycles until end of treatment, an expected average of 34 weeks"
            }, 
            {
                "description": "Cmax, Cmin, and half-life", 
                "measure": "Pharmacokinetics (Arm B, Arm C, Expanded Cohort B and Expanded Cohort C)", 
                "safety_issue": "Yes", 
                "time_frame": "Multiple timepoints in Cycles 1, 2, and 3 (4 weeks each) and Day 1 of remaining cycles until end of treatment, an expected average of 34 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}